British Journal of Clinical Pharmacology

Risk perception in drug therapy
pp. 135-137(3)
Author: Aronson, J. K

Erratum
pp. 137-137(1)

An update and appraisal of the cilomilast Phase III clinical development programme for chronic obstructive pulmonary disease
pp. 138-152(15)
Author: Giembycz, Mark A.

Effects of rac-albuterol on arterial blood gases in patients with stable hypercapnic chronic obstructive pulmonary disease
pp. 153-157(5)
Authors: Whale, Christopher I.; Sovani, Milind P.; Mortimer, Kevin; Oborne, Janet; Cooper, Sue; Harrison, Timothy W.; Tattersfield, Anne E.

Facial thermography is a sensitive tool to determine antihistaminic activity: comparison of levocetirizine and fexofenadine
pp. 158-164(7)
Authors: Larbig, Michael; Burtin, Bernard; Martin, Laurent; Stamm, Holger; Luettig, Birgit; Hohlfeld, Jens M.; Krug, Norbert

Development of a dosage strategy in patients receiving enoxaparin by continuous intravenous infusion using modelling and simulation
pp. 165-176(12)
Authors: Feng, Yan; Green, Bruce; Duffull, Stephen B.; Kane-Gill, Sandra L.; Bobek, Mary B.; Bies, Robert R.

The effect of CYP2J2, CYP3A4, CYP3A5 and the MDR1 ^C3435T polymorphisms and gender on the urinary excretion of the metabolites of the H₁-receptor antihistamine ebastine: a pilot study
pp. 177-186(10)
Authors: Gervasini, Guillermo; Vizcaino, Sonia; Carrillo, Juan Antonio; Caballero, Maria Jesus; Benitez, Julio

Poor correlation between 6β-hydroxycortisol:cortisol molar ratios and midazolam clearance as measure of hepatic CYP3A activity
pp. 187-195(9)
Authors: Chen, Ya-Chi; Gotzkowsky, S. Karl.; Nafziger, Anne N.; Kulawy, Robert W.; Rocci, Mario L.; Bertino, Joseph S.; Kashuba, Angela D. M.

Major determinant factors of the extent of interaction between grapefruit juice and calcium channel antagonists
pp. 196-199(4)
Authors: Ohnishi, Ayako; Ohtani, Hisakazu; Sawada, Yasufumi

Effect of widely used combinations of antiretroviral therapy on liver CYP3A4 activity in HIV-infected patients
pp. 200-209(10)
Authors: Mouly, Stéphane; Rizzo-Padoin, Nathalie; Simoneau, Guy; Verstuyft, Céline; Aymard, Guy; Salvat, Cécile; Mahé, Isabelle; Bergmann, Jean-François

Multiple doses of the antimuscarinic agent solifenacin do not affect the pharmacodynamics or pharmacokinetics of warfarin or the steady-state pharmacokinetics of digoxin in healthy subjects
pp. 210-217(8)
Authors: Smulders, R. A.; Kuipers, M. E.; Krauwinkel, W. J. J.

General practitioners' ranking of evidence-based prescribing quality indicators: a comparative study with a prescription database
pp. 218-224(7)
Authors: Okechukwu, Ifeanyi; Bennett, Kathleen; Feely, John

Using a capture-recapture method to assess the frequency of adverse drug reactions in a French university hospital
pp. 225-231(7)
Authors: Lugardon, Stephanie; Desboeuf, Karine; Fernet, Pierre; Montastruc, Jean-Louis; Lapeyre-Mestre, Maryse

Patients' knowledge of adverse reactions to current medications
pp. 232-236(5)
Authors: Cullen, Garret; Kelly, Emer; Murray, Frank E.

Induction of P-glycoprotein in lymphocytes by carbamazepine and rifampicin: the role of nuclear hormone response elements
pp. 237-242(6)
Authors: Owen, Andrew; Goldring, Chris; Morgan, Paul; Park, B. Kevin; Pirmohamed, Munir

Selectivity of NSAIDs for COX-2 and cardiovascular outcome
pp. 243-245(3)
Authors: Maxwell, S. R. J.; Payne, R. A.; Murray, G. D.; Webb, D. J.

A case of acute lead poisoning in a 2-year-old child
pp. 246-247(2)
Authors: Guillard, Olivier; Flamen, Patrick; Fauconneau, Bernard; Maurage, Chantal; Mauco, Gérard

Spontaneous retroperitoneal haematoma associated with clopidogrel therapy mimicking acute appendicitis
pp. 248-249(2)
Authors: Jurisic, Darko; Doko, Marko; Glavan, Elizabet; Vidovic, Dinko; Matkovic, Kristijan; Pitlovic, Vlatka

The effect of the CYP2C19*2 heterozygote genotype on the pharmacokinetics of nelfinavir
pp. 250-252(3)
Authors: Burger, David M.; Schwietert, H. Reinier; Colbers, E. P. H. (Angela); Becker, Mark

Pharmacogenomics, Methods and Protocols
pp. 253-253(1)

The Adrenergic Receptor in the 21st Century
pp. 254-255(2)